Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The primary antiphospholipid syndrome: Case report

  • 29 Accesses


Lupus anticoagulant antibodies and anticardiolipin antibodies are acquired circulating immunoglobulins that interact with phospholipids. These factors may exert anticoagulant properties in vitro and so interfere with coagulation tests that use phospholipids. These antibodies are not, however, associated with a hemorrhagic diathesis. Indeed, despite their name and their in vitro anticoagulant properties, they have been associated right from the earliest reports with systemic and cerebral thromboembolic episodes. We report the clinical and instrumental findings in a patient with ischemic stroke and anticoagulant antibodies in the serum.


Gli anticorpi anticoagulanti tipo-lupus e gli anticorpi anticardiolipina sono immunoglobuline circolanti acquisite che interagiscono con i fosfolipidi. Questi fattori, in vitro, possono manifestare proprietà anticoagulanti interferendo con i test della coagulazione che utilizzano fosfolipidi.

Tali anticorpi non sono tuttavia associati a diatesi emorragica. Infatti contrariamente al loro nome ed alle loro proprietà anticoagulanti in vitro, essi fin dalle loro prime descrizioni sono stati correlati ad episodi tromboembolici sistemici e cerebrali.

Vengono descritti i reperti clinici e strumentali osservati in una paziente con ictus ischemico e anticorpi anticoagulanti in circolo.

This is a preview of subscription content, log in to check access.


  1. [1]

    Asherson R.A., Gil, A., Vazquer, J.-J., Chan O., Baguley E., Hughes G.R.V.:Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am. J. Med. 86:391–399, 1989.

  2. [2]

    Bernard C., Moerloose P.:Anticorps anticardiolipins et thromboses. Méd. et Hyg. 48:166–169, 1990.

  3. [3]

    Briley D.P., Coull B.M., Goodnight S.H. Jr.:Neurological diseases associated with antiphospholipid antibodies. Ann. Neurol. 25:221–227, 1989.

  4. [4]

    Coull B.M., Goodnight S.H.:Antiphospholipid antibodies, prethrombotic states, and stroke. Stroke 21:1370–1374, 1990.

  5. [5]

    Digre K.B., Durcan F.J., Branch D.W., Jacobson D.M., Varner M.W., Baringer J.R.:Amaurosis fugax associated with antiphospholipid antibodies. Ann. Neurol. 25:228–232, 1989.

  6. [6]

    Futrell N., Millikan C.:Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke 20:583–591, 1989.

  7. [7]

    Hart R.G., Kanter M.C.:Hematologic disorders and ischemic stroke. A selective review. Stroke 21:1111–1121, 1990.

  8. [8]

    Inzelberg R., Korczyn A.D.:Lupus anticoagulant and late onset seizures. Acta Neurol. Scand. 79:114–118, 1989.

  9. [9]

    Kushner M., Simonian N.:Lupus anticoagulants, anticardiolipin antibodies and cerebral ischemia. Stroke 20:225–229, 1989.

  10. [10]

    The Antiphospholipid Antibodies in Stroke Study Group.Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke 21:1268–1273, 1990.

Download references

Author information

Correspondence to Dr. S. Severi.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Severi, S., Ghezzi, M. & Felici, M. The primary antiphospholipid syndrome: Case report. Ital J Neuro Sci 13, 599–601 (1992). https://doi.org/10.1007/BF02233404

Download citation

Key Words

  • Anticoagulants
  • antiphospholipid antibodies
  • thrombosis